1. Consolidated Sales Comparison
Company
Amt.in INR Cr
Amt in $ Million
OIPL - Domestic /ROW/Mango
156.60
23.73
189.00
28.64
OIUS - Export
48.00
7.27
37.00
5.61
Total OIPL
204.60
31.00
226.00
34.24
OI US - Net of Trade Discount
87.96
13.33
111.54
16.90
Clean
34.72
5.26
Total OI US
146.25
22.16
Consolidation Adjustment
Inter Co Sales to OI US
-48.00
-7.27
-37.00
-5.61
50 % Sale of Clean - - 
-17.36
-2.63
Net Consolidated Sale
244.56
37.05
317.89
48.17

2. Consolidated EBITDA for FY 2018-19
Company
Amt in INR Cr
Amt in $ Million
OI India
61.00
9.61
66.37
10.06
OI US
0.84
0.13
6.77
1.03
Clean Company ( 50%)
3.30
0.50
Total EBITDA
61.84
9.74
76.44
11.58
Add : Unrealised Profit for OIUS
-6.35
-1.00
6.60
1.00
Net Consolidated EBITDA
55.49
8.74
83.04
12.58
Note: We have assumed that at the end of FY , closing stock of OI US will reduced to USD 5 Mio, hence we have reversed (added) unrealised profits on differential closing stock i.e. USD 2 50%.

3. Corporate Expenses for the FY 2018-19
Dr. Junger CMO $120K
Sarada $100K
Misc. $80K
Total $300K

4. Investment in CIMED Initial Capital Infusion (80% stake) INR. 1.60 cr
Further Investment as secondary INR cr
(Enterprise Value of INR. 50 cr)
Total Investment INR cr
Less : Sale of Equipment to CIMED INR cr (approx.)
Net Investment INR cr
Note: CIMED will also get INR 10 cr from external investors at an enterprise value of INR. 50 cr.